AU2019282755B2 - Recombinant Herpes Simplex Virus for cancer immunotherapy - Google Patents

Recombinant Herpes Simplex Virus for cancer immunotherapy

Info

Publication number
AU2019282755B2
AU2019282755B2 AU2019282755A AU2019282755A AU2019282755B2 AU 2019282755 B2 AU2019282755 B2 AU 2019282755B2 AU 2019282755 A AU2019282755 A AU 2019282755A AU 2019282755 A AU2019282755 A AU 2019282755A AU 2019282755 B2 AU2019282755 B2 AU 2019282755B2
Authority
AU
Australia
Prior art keywords
cancer
protein
hsv
cells
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019282755A
Other languages
English (en)
Other versions
AU2019282755A1 (en
Inventor
Bin He
Xing Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois System filed Critical University of Illinois System
Publication of AU2019282755A1 publication Critical patent/AU2019282755A1/en
Application granted granted Critical
Publication of AU2019282755B2 publication Critical patent/AU2019282755B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2019282755A 2018-06-08 2019-06-07 Recombinant Herpes Simplex Virus for cancer immunotherapy Active AU2019282755B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682202P 2018-06-08 2018-06-08
US62/682,202 2018-06-08
PCT/US2019/035922 WO2019236931A1 (en) 2018-06-08 2019-06-07 Recombinant herpes simplex virus for cancer immunotherapy

Publications (2)

Publication Number Publication Date
AU2019282755A1 AU2019282755A1 (en) 2021-01-28
AU2019282755B2 true AU2019282755B2 (en) 2025-09-11

Family

ID=67070913

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019282755A Active AU2019282755B2 (en) 2018-06-08 2019-06-07 Recombinant Herpes Simplex Virus for cancer immunotherapy

Country Status (8)

Country Link
US (2) US12329794B2 (https=)
EP (1) EP3801583B1 (https=)
JP (1) JP7373209B2 (https=)
KR (1) KR102906757B1 (https=)
CN (1) CN112243378B (https=)
AU (1) AU2019282755B2 (https=)
CA (1) CA3142073A1 (https=)
WO (1) WO2019236931A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111635913B (zh) * 2020-06-16 2022-03-04 广东东阳光药业有限公司 构建体及其应用
CN113862229A (zh) * 2020-06-30 2021-12-31 东莞市东阳光生物药研发有限公司 一种重组单纯疱疹病毒及其构建方法
CN113943752A (zh) * 2020-07-15 2022-01-18 东莞市东阳光生物药研发有限公司 构建体、敏感性提高的溶瘤病毒及其应用
CN114075574A (zh) * 2020-08-19 2022-02-22 广东东阳光药业有限公司 构建体、溶瘤病毒及其应用
TW202521570A (zh) * 2023-08-25 2025-06-01 大陸商勃林格殷格翰動物保健（中國）有限公司 用於禽類疫苗的新型ｄｅｖ載體

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60115600T2 (de) * 2000-01-21 2006-07-20 Biovex Ltd. Virusstämme für die onkolytische behandlung von krebs
US7264814B2 (en) * 2001-05-09 2007-09-04 M's Science Corporation Composition and method for treating cancer using herpes virus
GB0714578D0 (en) * 2007-07-26 2007-09-05 Crusade Lab Ltd Viruses
ES2861450T3 (es) 2015-07-20 2021-10-06 Virttu Biologics Ltd Uso del virus del herpes simple oncolítico en combinación con un inhibidor de puntos de control inmunitario, en el tratamiento del cáncer
US20170319638A1 (en) 2016-05-06 2017-11-09 Virttu Biologics Limited Treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RYUICHI KANAI等: "Effect of v34.5 deletions on oncolytic herpes simplex virus activity in brain tumors", JOURNAL OF VIROLOGY, vol. 86, no. 8, 15 February 2012 (2012-02-15), pages 1 - 2 *

Also Published As

Publication number Publication date
US20250339482A1 (en) 2025-11-06
CN112243378A (zh) 2021-01-19
WO2019236931A1 (en) 2019-12-12
CA3142073A1 (en) 2019-12-12
US20210138009A1 (en) 2021-05-13
EP3801583A1 (en) 2021-04-14
AU2019282755A1 (en) 2021-01-28
KR20210022547A (ko) 2021-03-03
US12329794B2 (en) 2025-06-17
KR102906757B1 (ko) 2025-12-31
EP3801583B1 (en) 2025-07-02
JP7373209B2 (ja) 2023-11-02
CN112243378B (zh) 2024-12-31
JP2021527072A (ja) 2021-10-11

Similar Documents

Publication Publication Date Title
US20250339482A1 (en) Recombinant Herpes Simplex Virus for Cancer Immunotherapy
Manservigi et al. HSV recombinant vectors for gene therapy
CA3014504A1 (en) Smc combination therapy for the treatment of cancer
Nguyen et al. The current state of oncolytic herpes simplex virus for glioblastoma treatment
Scanlan et al. Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers
JP2020511160A (ja) 組み換え単純ヘルペスウイルス及びその使用
Zhang et al. Construction of an IL12 and CXCL11 armed oncolytic herpes simplex virus using the CRISPR/Cas9 system for colon cancer treatment
JP2022515823A (ja) ｍ２欠陥ポックスウイルス
US6897057B1 (en) Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
AU2001268146B2 (en) Use of mutant herpes viruses and anticancer agents in the treatment of cancer
WO2019043282A1 (es) Producto de combinación que comprende una célula madre mesenquimal modificada y una sustancia antigénica
Liu et al. Selective editing of herpes simplex virus 1 enables interferon induction and viral replication that destroy malignant cells
AU2001268146A1 (en) Use of mutant herpes viruses and anticancer agents in the treatment of cancer
US20240277792A1 (en) Oncolytic viruses and methods of use thereof for the treatment of cancer
Froechlich Dissecting the STING-dependent molecular mechanisms in a preclinical model of combined treatment with tumour-targeted Herpes simplex virus and immune checkpoint blockade
Watson Characterizing a novel viral sensitizer BI-D1870
Beauregard Type I Interferon-Mediated Killing of Cancer Cells with IAP-Targeted Combination Immunotherapy
EP1486212A1 (en) Combination of a mutant herepes virus and irinotecan for the treatment of cancer
Wongthida Understanding, and exploiting, the contribution of the immune system to the therapeutic efficacy of oncolytic virotherapy with vesicular stomatitis virus (VSV)
Rodrigues Characterization of Oncolytic Herpesviruses
Baird Development of a Novel Model for Exploring the Role of Regulatory T-cells in Oncolytic HSV Cancer Therapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)